At @ASNKidney #KidneyWk we’re presenting the latest data across our kidney disease portfolio. Stop by booth #588 and join us at our medical symposiums to learn about our ongoing work to address the unmet needs of this community.

#News: We’re attending @ASNKidney #KidneyWk to share data from our nephrology portfolio. Read more about our upcoming presentations: spr.ly/6012BHR9MG

#News: Biogen New Ventures is proud to participate in the Series A financing of Estuary Biotherapeutics, a company pioneering targeted gene therapies for autosomal dominant polycystic kidney disease (ADPKD). Learn more: spr.ly/6012BHzBe4

#News: Biogen New Ventures is proud to participate in Altay Therapeutics' Series A financing to support the development of an investigational oral therapy for facioscapulohumeral muscular dystrophy (FSHD). Learn more: bit.ly/4s2mBgW

We’re excited to be at #AAO2026 in New Orleans. Stop by Booth #2419 to learn more about our ongoing work to support people living with geographic atrophy (GA).

#News: Today, we announced long-term 52-week results from a Phase 2 study in people living with cutaneous lupus erythematosus (CLE). Read more: spr.ly/6018BGvbdr

Find us at the #EADVCongress at booth #2212 to dive into our evolving research in CLE, a serious and chronic autoimmune skin disease that currently has no targeted therapies.

Join us at #WMS2026 for our symposium where leading experts will discuss ongoing research in spinal muscular atrophy (SMA) and practical considerations for optimizing care for people living with SMA.

At #TTS2026 we're presenting key insights into antibody-mediated rejection (AMR) and microvascular inflammation (MVI). Join our symposium and stop by booth #15 and #16 to learn about Biogen's work in these complicated and burdensome forms of kidney disease.

#News: Today, the Clinical Journal of the American Society of Nephrology published results from a Phase 3 analysis in adolescents with C3G and primary IC-MPGN. Read more: bit.ly/476pxiU

We’re heading to New Orleans for #PsychCongress2026! Together with Supernus Pharmaceuticals, we’ll share the latest real-world evidence in postpartum depression (PPD). Attending? Connect with our team and visit us at booth 1041. Learn more: spr.ly/6016BGHj4y

At #EEC2026 we’re sharing the latest data from our investigational study for Dravet syndrome, exploring the disease’s underlying genetic cause. Stop by booth #38 and join us at our medical symposium to learn more about our work in this genetic and highly burdensome disease.

#News: With @StokeTx we’re presenting data on an investigational drug for Dravet syndrome at #EEC2026. Read more about these data: bit.ly/4cvvnO1

#News: We are attending #EEC2026 alongside @StokeTx to share our latest findings in Dravet syndrome. Read more about our upcoming presentations: bit.ly/4zMJicq

#News: We announced the completion of the acquisition of RayThera Inc. This acquisition marks another step in growing Biogen’s immunology portfolio, adding multiple potential assets for immune-mediated diseases. Read more: spr.ly/6012B1Dlmq

We’re attending #GlomConHawaii to share more about our approach to C3G and primary IC-MPGN. Stop by booth #25 to learn how Biogen is working to transform care in complement-driven and immune-mediated kidney diseases.

STARTING SOON: Join our Q2 2026 earnings call webcast at 8:30AM ET here: spr.ly/6015BEIIcd #Earnings $BIIB

Today, we reported our Q2 results, demonstrating progress toward our goal of sustainable revenue growth. Read more: bit.ly/4yNFlUk Forward-looking statements: biogen.com/forward-looking-s… #Earnings $BIIB

#News: Today @synapticure announced its new ataxia care program. We’re proud to help support important awareness efforts as a part of our commitment to the broader ataxia communities. Read more: bit.ly/4vwPwtC

Our team will be at the @asrsdocs Annual Meeting to share 7 research abstracts that highlight our understanding of geographic atrophy (GA), a leading cause of blindness. Stop by Booth #1101 to learn more about our work in GA.